<DOC>
	<DOCNO>NCT02329223</DOCNO>
	<brief_summary>This Phase III , multicenter , randomize , double-blind , placebo-controlled , parallel-group study evaluate efficacy safety omalizumab administer subcutaneously add-on therapy treatment adolescent adult participant 12 - 75 year receive diagnosis refractory chronic spontaneous uriticaria remain symptomatic despite standard-dosed non-sedating H1 antihistamine treatment .</brief_summary>
	<brief_title>Study Efficacy Safety Omalizumab Refractory Chronic Spontaneous Urticaria Patients</brief_title>
	<detailed_description />
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key Diagnosis chronic spontaneous urticaria refractory H1 antihistamine time randomization Chronic spontaneous urticaria diagnosis 6 month Key Weight le 20 kg Clearly define underlying etiology chronic urticaria chronic spontaneous urticaria Evidence parasitic infection Any skin disease chronic spontaneous urticaria chronic itch Previous treatment omalizumab Contraindications diphenhydramine History anaphylactic shock History current diagnosis ECG abnormalities indicate significant risk safety patient participate study History hypersensitivity omalizumab drug similar chemical class Pregnant nursing ( lactate ) woman</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Chronic spontaneous uriticaria</keyword>
	<keyword>Omalizumab</keyword>
</DOC>